Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/06/24
American Clinical Research Services Announces Strategic Acquisition of ElixiaBusiness Wire • 05/08/24
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/07/24
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/07/24
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive OfficerPRNewsWire • 04/23/24
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 03/20/24
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 02/27/24
Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/15/24
Aclaris Therapeutics shares torpedo on underwhelming dermatitis trial resultsProactive Investors • 01/10/24
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic DermatitisGlobeNewsWire • 01/10/24
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for AlopeciaGlobeNewsWire • 12/05/23
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 12/04/23
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)Zacks Investment Research • 11/16/23
Aclaris Therapeutics pulls arthritis drug research program; shares plummetProactive Investors • 11/13/23
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate UpdateGlobeNewsWire • 11/13/23
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/06/23